A detailed history of Azzad Asset Management Inc /Adv transactions in Abb Vie Inc. stock. As of the latest transaction made, Azzad Asset Management Inc /Adv holds 23,329 shares of ABBV stock, worth $3.9 Million. This represents 0.5% of its overall portfolio holdings.

Number of Shares
23,329
Previous 12,320 89.36%
Holding current value
$3.9 Million
Previous $1.91 Billion 122.51%
% of portfolio
0.5%
Previous 0.24%

Shares

29 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

Apr 19, 2024

BUY
$159.82 - $182.1 $1.76 Million - $2 Million
11,009 Added 89.36%
23,329 $4.25 Billion
Q4 2023

Apr 01, 2024

SELL
$137.6 - $154.97 $20,227 - $22,780
-147 Reduced 1.18%
12,320 $1.91 Billion
Q3 2023

Apr 01, 2024

BUY
$133.59 - $154.65 $28,855 - $33,404
216 Added 1.76%
12,467 $1.86 Billion
Q2 2023

Apr 01, 2024

BUY
$132.51 - $164.9 $82,288 - $102,402
621 Added 5.34%
12,251 $1.65 Billion
Q1 2023

Apr 01, 2024

BUY
$144.61 - $166.54 $221,976 - $255,638
1,535 Added 15.21%
11,630 $1.85 Billion
Q4 2022

Apr 01, 2024

BUY
$138.31 - $165.87 $582,008 - $697,980
4,208 Added 71.48%
10,095 $1.63 Billion
Q3 2022

Apr 01, 2024

BUY
$134.21 - $153.93 $790,094 - $906,185
5,887 New
5,887 $733 Million
Q2 2020

Apr 01, 2024

SELL
$73.37 - $98.18 $2.56 Million - $3.42 Million
-34,874 Closed
0 $0
Q1 2020

Apr 01, 2024

SELL
$64.5 - $97.79 $166,732 - $252,787
-2,585 Reduced 6.9%
34,874 $2.66 Billion
Q4 2019

Apr 01, 2024

BUY
$72.13 - $90.25 $85,546 - $107,036
1,186 Added 3.27%
37,459 $3.33 Billion
Q3 2019

Apr 01, 2024

BUY
$62.98 - $75.72 $279,442 - $335,969
4,437 Added 13.94%
36,273 $2.78 Billion
Q2 2019

Apr 01, 2024

BUY
$65.7 - $83.98 $321,798 - $411,334
4,898 Added 18.18%
31,836 $2.32 Billion
Q1 2019

Apr 01, 2024

BUY
$77.14 - $90.79 $122,884 - $144,628
1,593 Added 6.29%
26,938 $2.17 Billion
Q4 2018

Apr 01, 2024

BUY
$77.85 - $96.01 $140,207 - $172,914
1,801 Added 7.65%
25,345 $2.34 Billion
Q3 2018

Apr 01, 2024

BUY
$88.91 - $98.84 $29,073 - $32,320
327 Added 1.41%
23,544 $2.23 Billion
Q2 2018

Apr 01, 2024

BUY
$89.78 - $106.23 $2.08 Million - $2.47 Million
23,217 New
23,217 $2.15 Billion
Q1 2018

Apr 03, 2024

BUY
$92.01 - $123.21 $1.55 Million - $2.08 Million
16,888 Added 353.53%
21,665 $2.05 Billion
Q4 2017

Apr 03, 2024

BUY
$89.56 - $98.21 $427,828 - $469,149
4,777 New
4,777 $462 Million
Q4 2015

Apr 03, 2024

SELL
N/A
-22,121 Closed
0 $0
Q3 2015

Apr 03, 2024

BUY
N/A
2,053 Added 10.23%
22,121 $1.23 Billion
Q2 2015

Apr 03, 2024

SELL
N/A
-5,099 Reduced 20.26%
20,068 $1.35 Billion
Q1 2015

Apr 03, 2024

BUY
N/A
6,052 Added 31.66%
25,167 $1.47 Billion
Q4 2014

Apr 03, 2024

BUY
N/A
725 Added 3.94%
19,115 $1.25 Billion
Q3 2014

Apr 03, 2024

BUY
N/A
1,004 Added 5.77%
18,390 $1.06 Billion
Q2 2014

Apr 03, 2024

BUY
N/A
2,202 Added 14.5%
17,386 $981 Million
Q1 2014

Apr 03, 2024

BUY
N/A
1,316 Added 9.49%
15,184 $780 Million
Q4 2013

Apr 03, 2024

BUY
N/A
825 Added 6.33%
13,868 $732 Million
Q2 2013

Apr 03, 2024

BUY
N/A
823 Added 6.73%
13,043 $577 Million
Q1 2013

Apr 03, 2024

SELL
N/A
-100
12,220 $498 Million

Others Institutions Holding ABBV

About AbbVie Inc.


  • Ticker ABBV
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 1,768,099,968
  • Market Cap $296B
  • Description
  • AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...
More about ABBV
Track This Portfolio

Track Azzad Asset Management Inc /Adv Portfolio

Follow Azzad Asset Management Inc /Adv and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Azzad Asset Management Inc /Adv, based on Form 13F filings with the SEC.

News

Stay updated on Azzad Asset Management Inc /Adv with notifications on news.